爱普列特治疗良性前列腺增生症临床疗效观察  

The Clinical Efficacy of Epristeride in the Treatment of Benign Prostatic Hyperplasia

作　　者：李前跃[1] 王砺[1] 陈双峰[1] 王新会[1] 李志坤[1] 王剑[1] 朱红学[1] 

机构地区：[1]石河子大学医学院第二附属医院新疆乌鲁木齐兵团总医院,乌鲁木齐830002

出　　处：《中国医药导刊》2008年第7期1045-1046,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:临床研究评价新型非竞争性5α-还原酶抑制剂——爱普列特(Epristeride)治疗良性前列腺增生症(BPH)的安全性、有效性。方法:96例患者均经临床确诊为BPH,给爱普列特片5mg,Bid,po,4个月。以国际前列腺症状评分(IPSS),最大尿流率(Qmax),前列腺体积(PV)及残余尿(Ru)的变化率药物不良反应并作临床分析。结果:96例患者2例1～2个月后失访,94例均有效参加临床统计。服药前后IPSS、Qmax、PV、Ru的变化均有显著性差异(P<0.05)。4个月的总有效率为92.6%(87/94)。药物不良反应5例,未发生试验室检查异常。结论:爱普列特可明显改善BPH患者的排尿症状,缩小PV,增加尿流率,减少Ru,不良反应率低,是一种安全、有效治疗BPH的新药。Objective：To estimate the clinical saftely, efficacy of Epristeride in the treatment of benign, prostatic hyperplasia （BPH）.Method： Ninety-six BPHpatients, aged from 55 to 86 years old, average 66years old.Give way in which 5 mg epristeride was orally administered tewice a day . All four months. To synthetically estimate the efficacy by the changing rate of international prostate symptom score （IPSS）, maximum flow rate（Qmax）, the volume of prostate（PV）and the residual urine（Ru）.Results ： All Ninety-six patients jion the research, of tow patients lost research, after one ,two month. Through observe by the changing rate of the numerical analysis IPSS, Qmax, PV, Ru.The toal efficacy, was 92.6%（87/94）. The adverse reactions include 2 cases （2.1%） of nausea and vomiting, 1 case（1.1%） of exanthem and 2 cases （2.1%） of erectile dysfunction. There was no clinical significantly a bnormal laboratory index during the treatment. Conclusions： It was concluded that epristeride, a new type of 5α-reductase; is an ideal new drug tor patients with BPH.

关 键 词：爱普列特 良性前列腺增生 5Α-还原酶抑制剂 

分 类 号：R697.3[医药卫生—泌尿科学]